본문 바로가기
주메뉴 바로가기
뉴로바이오젠
ABOUT
Overview
History
CI
Affiliate Company
This is the way
BUSINESS
Vision & Motto
Pipeline
Tisolagiline(KDS2010)
COMMUNICATIONS
News
Announcements
R&D
Corporate R&D Center
Joint research Institute
IR
Announcement
Corporate Disclosure
CAREERS
Ideal Candidate
Employment Announce
ENG
KOR
ENG
COMMUNICATION
News
Announcements
News & Press Release
Uncover the secret of stroke that remains symptoms even after treatment...“Confirmed the efficacy of
DATE : 2020-07-08
VIEWS : 2430
FILES
PREV
Neurobiogen, applied for FDA ODD(Orphan Drug Designation) for 'Acute Spinal Cord Injury' treatment,
NEXT
NEUROBIOGEN, a new drug candidate,'KDS2010' registered for a patent in China.
LIST
Add
(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
Tel
+82-70-4018-8009
Fax
+82-02-3486-2613
E-mail
neuro_reply@neurobiogen.com
FAMILY SITE
(주)시너지이노베이션
(주)메디카코리아
(주)프로톡스
(주)인트로바이오파마
(주)엠아이텍
노비스바이오(주)
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved